Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
51. |
ECCT/24/10/01 | ALNASA A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Principal Investigator(s) 1. Videlis Nduba Nzioka Site(s) in Kenya 1. KEMRI-CRDR Clinical Research Annex (Nairobi City county) 2. Clinical Research Health Network (CREA-N) (Machakos county) 3. Center for Research In Tropical Medicine and Community Development (Nairobi City county) 4. KEMRI-Mtwapa Clinical Annex (Kilifi county) 5. University of Nairobi Clinical Research Centre (Nairobi City county) |
21-12-2024 |
View |
52. |
ECCT/24/07/04 | AMC-114 A Phase III, Randomized, Open-Label, Non-Inferiority Study of Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma in Resource-Limited Settings |
Principal Investigator(s) 1. Dr. Naftali Busakhala Site(s) in Kenya Moi University Clinical Research Center |
03-12-2024 |
View |
53. |
ECCT/24/02/07 | CO-SAM An adaptive multi-arm trial to improve clinical outcomes among children recovering from complicated severe acute malnutrition (CO-SAM) |
Principal Investigator(s) 1. Benson Singa Site(s) in Kenya 1. Homabay County Referral hospital (Homa Bay county) 2. Migori County Referral Hospital (Migori county) 3. Mbagathi County Referral Hospital (Nairobi City county) 4. Coast General Teaching and Referral Hospital (Mombasa county) |
03-12-2024 |
View |
54. |
ECCT/24/06/05 | SII-qHPV Vaccine Study A Phase-3b, partially double-blind, randomized, multi-country clinical study to evaluate the immunogenicity, safety, and reactogenicity of SIIPL qHPV vaccine (CERVAVAC®) in women living with HIV aged 15-25 years. |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya 1. KEMRI-CCR PHRD Thika (Kiambu county) 2. KEMRI - CCR Nairobi (Nairobi City county) |
26-11-2024 |
View |
55. |
ECCT/24/06/02 | ALNASA A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Principal Investigator(s) 1. Jesse Gitaka Site(s) in Kenya 1. Center for Research In Tropical Medicine and Community Development (Nairobi City county) 2. Clinical Research Health Network (CREA-N) (Machakos county) 3. KEMRI-Mtwapa Clinical Annex (Kilifi county) 4. University of Nairobi Clinical Research Centre (Nairobi City county) 5. KEMRI-CRDR Clinical Research Annex (Nairobi City county) |
25-11-2024 |
View |
56. |
ECCT/24/09/02 | ALNASA A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Principal Investigator(s) 1. Teresa Kinyari Site(s) in Kenya 1. University of Nairobi Clinical Research Centre (Nairobi City county) 2. KEMRI-Mtwapa Clinical Annex (Kilifi county) 3. Center for Research In Tropical Medicine and Community Development (Nairobi City county) 4. Clinical Research Health Network (CREA-N) (Machakos county) 5. KEMRI-CRDR Clinical Research Annex (Nairobi City county) |
13-11-2024 |
View |
57. |
ECCT/24/10/02 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Dr Isaac Tsikhutsu Site(s) in Kenya 1. Kenya Medical Research Institute/Walter Reed Project, Clinical Research Center (Kericho county) |
12-11-2024 |
View |
58. |
ECCT/24/06/04 | ALNASA A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Principal Investigator(s) 1. Jacqueline Mirera Site(s) in Kenya 1. Clinical Research Health Network (CREA-N) (Machakos county) |
23-10-2024 |
View |
59. |
ECCT/24/06/03 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL |
Principal Investigator(s) 1. Dr Walter Otieno Site(s) in Kenya 1. KEMRI-USAMRD-A Kombewa Clinical Research Centre (Kisumu county) |
20-09-2024 |
View |
60. |
ECCT/24/05/05 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL |
Principal Investigator(s) 1. Dr Kariuki Simon Kariuki 2. Patricia Odero Ojwang Site(s) in Kenya 1. Kenya Medical Research Institute-Dr Kariuki (Kisumu county) |
29-08-2024 |
View |